Skip to main content

Artificial Intelligence is a growing industry with a wide range of uses. AI has become a crucial part of advancing digital pathology, especially when it comes to improving patient care and the biopsy process. AI supports pathologists during multiple stages of their digital workflow to save them time and improve cancer diagnosis.  

Traditionally, multiple pathologists would physically examine a tissue sample on a glass slide under a microscope to search for and diagnose cancer. Over the years, the number of pathologists has been declining as the amount of biopsies increases, overwhelming pathologists and their outdated tech. Even with the advantages that come from the adoption of digital pathology across many practices, pathologists’ workloads continue to grow. 

Several companies have made it their mission to provide AI that integrates with digital pathology. Artificial intelligence can improve diagnoses with its ability to detect patterns invisible to the human eye. It can also assist with menial but essential tasks that take a significant workload off of the pathologist, allowing for more time to focus on interpreting data for more cases. Now patients can have faster and more accurate results, leading to better treatment plans. Here are the top 10 companies leading the charge in providing artificial intelligence for digital pathology:

Logos for the AI companies

Aiforia: Aiforia’s cloud based products and services are designed to decrease the burdens experienced by pathologists due to their outdated equipment. Aiforia also aims to reduce the wait time for patients and create more reliable treatments by providing them with accurate diagnoses and treatment plans.  

AIRA Matrix: Based in India and primarily focused on prostate cancer, AIRA Matrix strives to provide artificial intelligence solutions that improve efficiency, diagnostic accuracy and turnaround times in pathology lab workflows. They work with hospitals, pharmaceutical companies, CROs, and research labs around the world to improve outcomes for the patients.  

Deep Bio: Based in South Korea, Deep Bio has the goal of driving innovation in technology, providing clinicians with the tools to make critical decisions, and improve patient outcomes. They recognize the gap between pathologists based on their areas of experience is causing inconsistencies for diagnoses and are working to bridge that gap with artificial intelligence. Their AI is a deep learning-based cancer diagnostic support software that is designed to unlock personalized insights for clinicians and strengthen healthcare delivery to support both clinicians and patients. 

DoMore Diagnostics: Based in Oslo, Norway, DoMore Diagnostics has developed its own artificial intelligence with the goal of reducing the over and undertreatment of cancers and improving drug development. In doing so, they have developed AI that provides fully automated histotyping that can guide the selection of therapy to provide patients with the correct treatment. 

Indica Labs: Based in New Mexico, USA, Indica Labs utilizes artificial intelligence to provide solutions that streamline image analysis and workflow for digital pathology. Specifically, they use their products HALO and HALO AI to evaluate and manage images. They also have a Pharma Services team that uses their software to source image analysis and bioinformatics services to institutes and organizations. 

Mindpeak: Based in Hamburg, Germany, Mindpeak recognizes that the demand for diagnosis is rising while the number of pathologists is decreasing. Mindpeak’s mission is specifically to make diagnosing easier, allowing pathologists to focus on other tasks where their human expertise is indispensable while the AI takes care of the repetitive, tedious tasks. 

Paige AI: Based in New York City, Paige AI is working to provide additional information from digitized slides to help pathologists improve their efficiency and find novel insights that can’t be seen by the naked eye. In doing so, they will guide treatment and other decisions for diagnostic, pharmaceutical and life sciences companies. These findings with their AI will also match patients to clinic trials and therapies and enable pathologists to access the information from anywhere. 

Path AI: Path AI uses their AI to get accurate results that are reproducible, and focuses on using their AI to predict the response of the samples to new therapies and determine what will work best for the patient. Path AI also strives to improve patient outcomes by creating a more accurate treatment plan. 

Tempus: Tempus AI is centered on diagnosing patients earlier so they can find out which specific therapies they qualify for, including clinical trials. They have one of the world’s largest libraries of clinical and molecular data, which enables physicians to make faster data-driven decisions to create personalized care for each patient. 

Verily: Verily is an Alphabet company that is bringing precision healthcare to everyone, everyday. According to Verily, healthcare and patient diagnosis have been more of a “one size fits all” view as opposed to treatment plans created specifically for each patient. Their up and coming AI will address this issue to provide quality and personalized treatment plans for all patients. 

Artificial intelligence helps  determine the best treatment options for patients by accurately identifying and diagnosing tissue samples. New developments in AI are advancing digital pathology, creating opportunities for a vast amount of improvements. In the past 7 years, many companies around the globe have developed and tested artificial intelligence with no signs of slowing down. As companies continue to develop and utilize machine learning in cancer diagnostics, benefits for both patients and pathologists will be astronomical. Lumea and other digital pathology companies are teaming up with AI to bring the best diagnostics possible to cancer patients. 

Leave a Reply